Researchers advocate better access to angioplasty treatment

November 30, 2012
Researchers advocate better access to angioplasty treatment
Credit: Shutterstock

New research from the United Kingdom has found that primary angioplasty does increase the survival rate of heart attack patients. The Imperial College London researchers said recent studies examining the role of specialist heart attack centres generated misleading results, because physicians tend to allocate the best care to high-risk patients. They have discovered that the lack of benefit indicated in clinical records is an outcome of the sickest patients being sent to the specialist centres, effectively skewing the data. The finding was recently presented in the journal Circulation: Cardiovascular Quality and Outcomes.

Physicians in the United Kingdom usually send most to specialist centres for primary angioplasty, an operation that reopens blocked . Randomised trials showed that angioplasty gives patients a greater chance of surviving than drug treatment alone. However, past studies based on 'real-world' data indicate that patients given an angioplasty do not fare better. For the purposes of their study, the team from Imperial College London took the bias of skewed data into account, observing that primary angioplasty cuts the death rate from heart attacks by 22 %.

According to the researchers, their data confirm that heart attack centres are effective and should be more widely available. The data show that 82 % of heart attack patients in England and 30 % in Wales have access to primary . They also found wide discrepancies in access between regions.

'There has been some debate in the cardiology community about whether it is worthwhile to run specialist heart attack centres, despite evidence from clinical trials that they save lives,' said co-author Dr Iqbal Malik from the National Heart and Lung Institute at Imperial College London. 'This study resolves an important question. We must strive to make sure everyone in the UK has access to the best in the event of a heart attack.'

The team cautioned that in today's world, physicians who treat very sick patients tend to give them the most effective possible treatment. Called 'allocation bias', this phenomenon is good medical practice but can make 'comparative effectiveness' research unreliable. Adjusting for this bias is hard because doctors may base their decisions on many features that are difficult to document. So the researchers developed a method to help their peers detect when a disease is vulnerable to this form of bias in evaluation of its treatments.

'Comparing treatments based on clinical records will always be hindered by the good wisdom of the first-line doctors, who choose the most effective therapy for the most sick patients,' explained Dr Sayan Sen from Imperial College London, the lead author of the study. 'We demonstrate that decisions regarding the therapy of patients should be tested in the most reliable way, namely a randomised trial, and should not rely on registries.'

Explore further: Life-saving role of heart attack centers confirmed in new study

More information: Sen, S. et al., 'Why does primary angioplasty not work in registries? Quantifying the susceptibility of real-world comparative effectiveness data to allocation bias', Circulation: Cardiovascular Quality and Outcomes, 2012. doi:10.1161/CIRCO

Related Stories

Life-saving role of heart attack centers confirmed in new study

November 13, 2012
Recent studies questioning the role of specialist heart attack centres produced misleading results because doctors tend to send the sickest patients to have the best care, according to new research.

Hospital heart attack death rates improving but very elderly still missing out

October 19, 2011
Despite substantial reductions in the hospital death rates for heart attack patients across all age groups, there are still worrying inequalities in heart attack management for the elderly, a new study has shown.

Most hospitals miss critical window for heart attack transfer patients

November 28, 2011
Most heart attack patients transferred between hospitals for the emergency artery-opening procedure called angioplasty are not transported as quickly as they should be, Yale School of medicine researchers report in the first ...

Patients fare just as well if their nonemergency angioplasty is performed at hospitals

November 14, 2011
Hospitals that do not have cardiac surgery capability can perform nonemergency angioplasty and stent implantation as safely as hospitals that do offer cardiac surgery. That is the finding of the nation's first large, randomized ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.